lupus nephritis
Rheumatology · 2011–2026
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| obinutuzumab Treatment of patients with active class III or IV lupus nephritis with or without class V who are receiving standard therapy with mycophenolate mofetil and… | Mar 2026 | Recommended with restriction | input received Kidney Health Australia · Global Healthy Living Foundation · Creaky Joints Australia · Arthritis Australia · Australian Rheumatology Association · Australasian Society of Clinical Immunology and Allergy |
| mycophenolate sodium Induction and maintenance treatment of adult patients with biopsy-proven WHO Class III, IV or V lupus nephritis. | Jul 2012 | Recommended with restriction | no section in document |
| mycophenolate sodium Induction and maintenance treatment of adult patients with biopsy-proven WHO Class III, IV or V lupus nephritis. | Jul 2012 | Recommended with restriction | no section in document |
| mycophenolate sodium Induction and maintenance treatment of adult patients with biopsy-proven WHO Class III, IV or V lupus nephritis. | Nov 2011 | Recommended with restriction | unclear |
Who spoke
Kidney Health Australia · Global Healthy Living Foundation · Creaky Joints Australia · Arthritis Australia · Australian Rheumatology Association · Australasian Society of Clinical Immunology and Allergy
What the PBS pays
$85M in government benefit over 2024–25, across 222,338 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| obinutuzumab | $57.6M |
| mycophenolate sodium | $27.7M |
Appraised elsewhere
NICE, in England and Wales, has appraised 3 technologies for this condition, recommending 2 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| obinutuzumabObinutuzumab with mycophenolate mofetil for treating lupus nephritis | TA1131 | recommended restricted | 2026-02 |
| voclosporinVoclosporin with mycophenolate mofetil for treating lupus nephritis | TA882 | recommended restricted | 2023-05 |
| belimumabBelimumab for treating lupus nephritis (terminated appraisal) | TA806 | terminated | 2022-07 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.